Plain-English translation of NCT05759468 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a supplement called MIB-626 (a form of NMN, a naturally occurring compound) can help protect your kidneys if you have type 2 diabetes. Researchers believe this medication may reduce the amount of protein leaking into your urine—a sign of kidney damage. Half of the participants will take the real supplement, and half will take a placebo (a dummy pill), so researchers can see if the medication truly makes a difference.
Diabetes can slowly damage the kidneys over time, and current treatments don't work for everyone. Researchers are hoping that this medication will offer a new way to slow or prevent this damage before it becomes more serious.
You likely qualify if…
You likely don't qualify if…
You will take tablets twice a day for the duration of the study—either the real medication or a placebo, which you won't know which one. The study involves two medical centers and will enroll about 156 people total. You'll have regular visits where your urine and blood will be tested to measure how your kidneys are responding. The researchers are looking to see whether the medication reduces the amount of protein in your urine compared to the placebo group.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
Brigham and Women's Hospital
Collaborators
Boston Medical Center
Enrollment target
~156 participants
Started
April 2023
Primary completion
November 2026
Age range
30 Years and older
Last updated on clinicaltrials.gov in April 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Shalender Bhasin, MD
Brigham and Women's Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.